As part of its OncView™ program, CancerNetwork hosted a discussion Lori Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital in Boston, who shared her perspective on updates in the treatment of second-line radioiodine-refractory differentiated thyroid cancer, or DTC.

In the video series, some of the content discussed included:

·      Presentation and Disease Course of Differentiated Thyroid Cancer

·      Frontline Treatment Options for RAI-refractory DTC

·      Treatment Options in RAI-refractory DTC in Second Line and Beyond

·      Facing Unmet Needs and Ongoing Trials in RR-DTC

To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview. 

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.